Recordati offers a wide range of innovative medicines, mainly for cardiovascular and urological disorders, and unique treatments for rare diseases.

Dedicated to treating the most vulnerable. Orphan Europe and Recordati Rare Diseases, two Recordati companies dedicated to treatments for rare diseases.

We are also present in the self-medication segment and have always been committed to the improvement of quality of life by offering successful products with well-known brands.

New products, new clinical trials, new projects in new therapeutic areas: these are Recordati’s commitments and are a fundamental premise for its growth.

Last News RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA +7.4%, NET INCOME +6.1% Business & financial news

Recordati is a respected international pharmaceutical group and partner of important companies. >>

Rare Diseases

Each person with a rare disease has the right to the best treatment. >>

Research & Development

With an eye on the future the Recordati group invests significantly in research and development. >>

International Presence

Towards a global presence, a strategy of international development. >>

Committed to generating future value by enacting an intelligent partnering policy. >>

Share Price - Investors

“The most valuable currency in financial markets is reliable information”.

(Michael Bloomberg, Mary Shapiro)

Annual Report

Corporate Brochure

The Prize

Alert Service

Italiano | English

Company data RECORDATI S.p.A. VIA M. CIVITALI, 1 - 20148 MILAN, ITALY
SHARE CAPITAL € 26.140.644,5 i.v.
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150 CODICE FISCALE/P. IVA 00748210150
R.E.A. MILANO 401832
Company subject to the Management and Coordination Activities of Rossini Luxembourg S.àr.l

delivered by Tech Style

Site Services

Latest News

30 July 2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA +7.4%, NET INCOME +6.1% 12 July 2019 RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699)